Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

ChromaDex Shares Findings From A Preclinical Study; Shows Exogenous Nicotinamide Mononucleotide Must Be Converted To Nicotinamide Riboside, Making NR A More Efficient Nicotinamide Adenine Dinucleotide Precursor To NMN

Author: Benzinga Newsdesk | August 24, 2023 08:42am

This study, which utilized the gold standard method of stable isotopes, reinforces that NMN cannot cross the cell membrane directly and must first be converted to NR

Posted In: CDXC


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist